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The secretion and activation of the major cathepsin
L1 cysteine protease involved in the virulence of the
helminth pathogen Fasciola hepatica was investigated.
Only the fully processed and active mature enzyme can
be detected in medium in which adult F. hepatica are
cultured. However, immunocytochemical studies re-
vealed that the inactive procathepsin L1 is packaged in
secretory vesicles of epithelial cells that line the para-
site gut. These observations suggest that processing and
activation of procathepsin L1 occurs following secretion
from these cells into the acidic gut lumen. Expression of
the 37-kDa procathepsin L1 in Pichia pastoris showed
that an intermolecular processing event within a con-
served GXNXFXD motif in the propeptide generates an
active 30-kDa intermediate form. Further activation of
the enzyme was initiated by decreasing the pH to 5.0 and
involved the progressive processing of the 37 and 30-
kDa forms to other intermediates and finally to a fully
mature 24.5 kDa cathepsin L with an additional 1 or 2
amino acids. An active site mutant procathepsin L, con-
structed by replacing the Cys26 with Gly26, failed to au-
toprocess. However, [Gly26]procathepsin L was pro-
cessed by exogenous wild-type cathepsin L to a mature
enzyme plus 10 amino acids attached to the N terminus.
This exogenous processing occurred without the forma-
tion of a 30-kDa intermediate form. The results indicate
that activation of procathepsin L1 by removal of the
propeptide can occur by different pathways, and that
this takes place within the parasite gut where the pro-
tease functions in food digestion and from where it is
liberated as an active enzyme for additional extracorpo-
real roles.
Fasciola hepatica is a helminth parasite that causes liver
fluke disease in cattle and sheep worldwide and has recently
emerged as an important pathogen of humans (1). Cathepsin
L1, a major cysteine protease secreted by the parasite plays a
pivotal role in various aspects of its pathogenicity. For exam-
ple, the enzyme takes part in nutrient acquisition by catabo-
lizing host proteins to absorbable peptides (2), facilitates the
migration of the parasite through the host intestine and liver
by cleaving interstitial matrix proteins such as fibronectin,
laminin, and native collagen (3), and is implicated in the inac-
tivation of host immune defenses by cleaving immunoglobulins
(4, 5). Further, cathepsin L1 has recently been shown to sup-
press Th1 immune responses in infected laboratory animals
making them susceptible to concurrent bacterial infections (6,
7, 8). Accordingly, the protease has been recognized as an
important target at which parasite intervention strategies
should be directed (9). In this regard, we have shown that the
induction of anti-cathepsin L immune responses prior to a
challenge infection of F. hepatica larvae elicits high levels of
protection in cattle against disease (10, 11, 12).
Phylogenetic studies have shown that the F. hepatica cathep-
sin L1 belongs to an enzyme lineage that eventually gave rise
to the mammalian cathepsin Ls, Ks, and Ss (2). The isolation of
a cDNA encoding F. hepatica cathepsin L revealed that the
enzyme, like its mammalian homologs, is synthesized as an
inactive preproenzyme consisting of a prepeptide, a propeptide
and mature enzyme region (13). By analogy with the mamma-
lian proteases we assume that the prepeptide is removed fol-
lowing translocation into the endoplasmic reticulum and that
the N-terminal propeptide extension is involved in several
functions including intracellular targeting of the enzyme (14–
16), correct folding of the mature enzyme by acting as an
intramolecular chaperone (17–19) and prevention of uncon-
trolled proteolysis by binding to the enzyme substrate cleft in a
reverse, non-productive direction (14). As has been demon-
strated for the propeptide of human cathepsin L and other
papain-like cysteine proteases (14, 17, 19, 20) the free propep-
tide of the F. hepatica procathepsin L is a specific and potent
inhibitor of the cognate mature enzyme at neutral pH but does
not bind to the enzyme at pH 5.5–3.5 (21).
Human lysosomal procathepsin L is stable at high pH be-
cause the propeptide protects the protein from the denaturing
effects of the alkali (15). Removal of the propeptide to generate
the fully active mature enzyme occurs at the lower lysosomal
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pH of 5.5 (14, 15, 22, 23). It has been widely reported that
cleavage of the proregion of cysteine proteases can occur auto-
catalytically in vitro under acidic conditions (15, 24, 25, 26). As
the stability of the propeptide-protease complex is dependent
on electrostatic interactions, reduction of the environmental
pH, weakens the bond between the propeptide and the catalytic
site. As a consequence, the proenzyme possibly adopts a looser
conformation, in which the propeptide is bound less tightly
into the active site making it more susceptible to proteolysis
(16, 27).
The precise mechanism of proteolytic conversion from proen-
zyme to mature enzyme is still actively debated. The three-
dimensional structure of procathepsin L (14) and procathepsin
B (28, 29, 30) show that the N terminus of the mature enzyme
is quite removed from the active site thus making it difficult to
visualize an autocatalytic cleavage event. Moreover, circular
dichroism studies reveal that activation does not involve sig-
nificant conformational changes in the structure of procathep-
sin L (15) or procathepsin B (16). Therefore, the initial event in
autocatalysis may involve an active proenzyme, possibly cre-
ated by the reduced pH, that cleaves another proenzyme in the
vicinity of the N terminus and sets off a chain reaction (15, 16).
However, more recent studies on procathepsin B and proca-
thepsin S identified autoproteolytic intermediates of processing
when cystatin was included in in vitro activation reactions,
which supported the view that the segment of the propeptide
that binds the active site cleft is susceptible to cleavage (31).
Accordingly, it was suggested that an initial slow intramolec-
ular cleavage event within this segment of the propeptide trig-
gers a more rapid cascade of intermolecular cleavages at the N
terminus (31).
Earlier studies on the processing of yeast-expressed recom-
binant papain identified a conserved heptapeptide (Gly-Xaa-
Asn-Xaa-Phe-Xaa-Asp) motif located between residues 42
and 36 in the propeptide that may be a site of initial cleavage
in the pH-dependent autoactivation of the enzyme (32). It was
suggested that the lowering of the pH perturbed the negative
charge of Asp36 resulting in a conformational change that
switched on the processing events by allowing proteolysis to
occur at the Ala37/Asp36 bond. Following this primary cleav-
age further removal of the remaining amino acids of the
propeptide may result from the proteolytic activity of the in-
termediate species, resulting in fully active mature protease
(32).
Given the importance of cathepsin L proteases in the viru-
lence of F. hepatica and other helminth pathogens (2) it is
important to understand the mechanisms of their synthesis,
processing and activation. We have previously shown that ca-
thepsin L1 is secreted by this parasite and therefore functions
extracellularly (4, 33) similar to the mammalian cathepsin Ls
involved in the processing of the hormone thyroglobulin (34–
36). In the present study we have employed confocal laser and
electron immunocytochemistry to show that the enzyme is
stored in secretory vesicles of the gastrodermal epithelial cells
in its inactive proenzyme form. We investigate the autoactiva-
tion of F. hepatica cathepsin L1 using the wild-type proenzyme
expressed in Pichia pastoris. Intermolecular processing was
studied by generating an inactive procathepsin L mutant,
where the catalytic Cys residue at position 26 was substituted
with a Gly, which was incapable of autoactivation. Our results
show that P. pastoris-expressed cathepsin L can autoactivate
at low pH to an active intermediate form by an initial cleavage
within the conserved heptapeptide (Gly-Xaa-Asn-Xaa-Phe-
Xaa-Asp), as previously described for papain (32). Further ac-
tivation of the enzyme occurs by cleavage in the vicinity of the
N terminus. In contrast, intermolecular processing of the mu-
tant inactive procathepsin L to a mature product by exogenous
mature cathepsin L did not involve the formation of the above
intermediate but was initiated by a direct cleavage close to
the N terminus. These data provide a mechanism by which
F. hepatica synthesizes and secretes a fully activated protease
that is essential to its existence as a parasite.
EXPERIMENTAL PROCEDURES
Materials—Z-Phe-Arg-NHMec1 and Z-Phe-Ala-CHN2 were obtained
from Bachem (St. Helens, UK). DTT and EDTA were obtained from
Sigma (Dorset, Poole, UK). Prestained molecular weight markers and
the AvrII and SnaBI restriction enzymes were obtained from New
England Biolabs (UK) Ltd. (Hitchin, UK). Primers were obtained from
Sigma-Genosys (Pampisford, UK). The pPIC9K vector and Pichia
pastoris strain GS115 were obtained from Invitrogen Corp. (San
Diego, CA). Ni-NTA agarose and columns were obtained from Qiagen
(Crawley, UK).
In Vitro Cultivation of Parasites—Adult F. hepatica were obtained
from infected cattle at a local abattoir and cultured in vitro in RPMI
1640 containing 30 mM HEPES, 1% glucose and 25 mg/ml gentamycin
as described by Dalton and Heffernan (37). The medium was collected
after 6 h, cleared by centrifugation at 14,000  g for 30 min at 4 °C and
stored at 20 °C.
Preparation of Antipropeptide and Antimature Cathepsin L1 Anti-
sera—Native mature cathepsin L1 (nFheCL1) was purified from excre-
tory-secretory (ES) products of adult F. hepatica by gel permeation and
ion exchange chromatography and antiserum prepared in rabbits as pre-
viously described (4, 38). Recombinant cathepsin L1 propeptide was gen-
erated and purified as described by Roche et al. (21) and antiserum
prepared by immunizing New Zealand White rabbits five times with 20
g of protein formulated in Freund’s Complete and Incomplete Adjuvant.
Immunofluorescence and Immunoelectron Microscopy—Adult F. he-
patica were recovered from infected cattle at a local abattoir, washed,
and transported to the laboratory in mammal saline (0.9% NaCl) at
37 °C. Parasites were rinsed in mammal saline and allowed to regur-
gitate their gut contents before being flat-fixed in 4% paraformaldehyde
(PFA) in PBS (pH 7.2) for 4 h. They were washed in antibody diluent
(ABD: PBS with, 0.1% bovine serum albumin; 0.3% Triton X-100; 0.1%
sodium azide) for 24 h before being incubated for 48 h at 4 °C in
antiserum prepared against purified mature cathepsin L1 (diluted
1:3000) and subsequently washed in ABD (24 h, 4 °C). Swine anti-
rabbit tetramethyl rhodamine isothiocyanate (TRITC; 1:100; Dako Ltd.)
was used to visualize bound primary antibody before the worms were
washed in ABD (24 h, 4 °C) and mounted on glass microscope slides in
PBS/glycerol (1:9) containing 2.5% 2,4-diazabicylco 2.2.2 octane. Spec-
imens were viewed using a Leica TCS-NT confocal scanning laser
microscope.
For electron microscopy worms were washed in mammal saline and
fixed for 1 h in 2% double-distilled glutaraldehyde (GTA) (Agar Scien-
tific) in 0.1 M sodium cacodylate buffer (pH 7.2) containing 3% sucrose
at 4 °C. Following thorough washing in buffer, specimens were dehy-
drated through graded ethanol to propylene oxide, infiltrated and em-
bedded in Agar 100 resin (Agar Scientific). Ultrathin sections (80–90
nm) were cut on a Reichert Ultracut E ultramicrotome, collected on bare
200-mesh nickel grids and dried at room temperature. For immunogold
labeling sections were etched with 10% hydrogen peroxide for 5 min and
rinsed thoroughly with 20 mM Tris-HCl buffer (pH 8.2) containing 0.1%
bovine serum albumin and Tween 20 (1:40 dilution). Grids were incu-
bated in normal goat serum (1:20 dilution) for 30 min and then trans-
ferred to primary antibody diluted to 1:20,000 with 0.1% bovine serum
albumin/Tris-HCl buffer for 12–18 h. Grids were then washed in bovine
serum albumin/Tris-HCl and transferred to a 20 l drop of 10 nm
gold-conjugated goat anti-rabbit IgG (Bio Cell International) for 2 h at
room temperature. Following another buffer wash, grids were lightly
fixed with 2% double-distilled GTA for 3 min, and finally washed with
buffer and rinsed with distilled water. Grids were double stained with
uranyl acetate (5 min) and lead citrate (3 min) and examined in a FEI
(Philips) CM100 transmission electron microscope, operating at 100 keV.
Controls consisted of (i) incubation of whole-mounts/sections with
secondary antibody in the absence of primary antibody and (ii) incuba-
tion with preimmune serum followed by the secondary antiserum.
1 The abbreviations used are: Z-Phe-Arg-NHMec, benzyloxycarbonyl-L-
phenylalanyl-L-arginine 4-methylcoumarinyl-7-amide; Z-Phe-Ala-CHN2,
benzyloxycarbonyl-L-phenylalanyl-L-alanine-diazomethylketone; DTT, di-
thiothreitol; PBS, phosphate-buffered saline; NTA, nitrilotriacetic acid.
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Construction of Expression Vectors Encoding cDNA for Wild-type
Procathepsin L1 (rFheproCL1) and Gly26 Procathepsin L1 (rmutFhepro-
CL1) and Transformation into Pichia pastoris—The F. hepatica proca-
thepsin L (FheproCL1) was amplified by PCR from the pAAH5 Saccha-
romyces cerevisiae expression vector into which the full-length cDNA
had been previously cloned in our laboratory (13). Primers were used
(see primers A and D below) to incorporate a SnaBI restriction site at
the 5-end of the gene and an AvrII restriction site and His6 tag
sequence at the 3-end. The 980-bp fragment was inserted into the
AvrII/SnaB1 site of P. pastoris expression vector pPIC9K (Invitrogen).
Mutants were generated from this construct by a PCR-based site-
directed mutagenesis method known as gene splicing by overlap extension
(SOEing) (39) using the pPIC9K-FheproCL1 DNA as a template. The
construction of the inactive FheproCL1 mutant involved changing the
active site cysteine (Cys26) residue to a glycine in a two-step PCR process.
The primers used were as follows: primer A, 5-GCGGCTACGTATCGA-
ATGATGATTTGTGGCAT-3; primer B, 5-GAATGCCCAACCGGAGCC-
AC-3; primer C, 5-GTGGCTCCGGTTGGGCATTC-3; primer D, 5-GC-
GCCTAGGTCAGTGGTGGTGGTGGTGGTGGGCCC-3.
The underlined nucleotides indicate the replacements introduced.
Each reaction used one flanking primer that hybridized at one end of
the target sequence (primer A or D) and one overlapping internal
primer that hybridizes at the site of the mutation and contains the
mismatched base (primer B or C). In the first round of amplification two
sections of the cDNA were amplified using primer combinations AB
and CD. These two PCR products, with an overlap of 21 bp at one end
of each fragment, were then combined in a second PCR to amplify the
entire rmutFheproCL1 cDNA. Primers for this reaction were the two
outside primers used in each of the two first round reactions (primers A
and D). For all PCRs, high-fidelity Taq polymerase was used (25 cycles
at 94 °C for 30 s, 55 °C for 1 min, and 72 °C for 2 min). The rmutFhep-
roCL1 cDNA was then inserted into the AvrII/SnaB1 site of expression
vector pPIC9K. Both the wild-type (rFheproCL1) and mutant (rmutF-
heproCL1) plasmid insert were sequenced to verify the presence of
correct gene sequence and mutation.
The rFheCLI or rmutFheCL1 plasmids were linearized by digestion
with SalI and introduced to P. pastoris GSII5 cells by spheroplasting
(40). Transformants were selected for their ability to grow on histidine-
deficient agar plates and on agar plates containing minimal media and
methanol. Insertion of rFheCLI or rmutFheCL1 into P. pastoris was
confirmed by PCR using primers specific to the yeast genome (41).
Expression and Purification of Procathepsin L1 and Gly26 Procathep-
sin L1—Yeast transformants were cultured in 250 ml of BMGY broth,
buffered to pH 6.0, in 1 liter of baffled flasks at 30 °C until an OD600 of
2–6 was reached. Cells were harvested by centrifugation at 2000 rpm
for 5 min, and protein expression induced by resuspending in 50 ml of
BMMY broth, buffered at pH 6.0, 7.0, or 8.0, containing 1% methanol
(41). The cultures were grown at 30 °C with shaking at 225 rpm for 3
days, 1 ml samples were removed daily and then filter-sterilized meth-
anol was added to maintain a final concentration of 1%. To assess the
effect of the cathepsin L cysteine inhibitor Z-Phe-Ala-diazomethyl-
ketone (-CHN2) on the production of procathepsin L1 by yeast the
inhibitor was added at the time of induction to a final concentration of
25 M and then twice daily at the same concentration over the subse-
quent 3 days.
Recombinant proteins were purified from yeast medium by affinity
chromatography using Ni-NTA-agarose (Qiagen). Briefly, a column pre-
pared with 1 ml of resin was equilibrated by passing through 10 ml of
50 mM sodium phosphate buffer, pH 8.0, containing 300 mM NaCl and
10 mM imidazole. 10 ml of yeast media supernatant was mixed with 40
ml of the same buffer and applied to the column. The column was
washed with 15 ml of 50 mM sodium phosphate buffer, pH 8.0, contain-
ing 300 mM NaCl and 20 mM imidazole, and bound protein eluted using
50 mM sodium phosphate buffer, pH 7.0, containing 300 mM NaCl and
250 mM imidazole. Purified recombinant proteases were dialysed
against PBS and stored at 20 °C. Samples of yeast medium superna-
tants (10 l) and purified proteins (1–5 g) were analyzed by 12%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot-
ting (see below).
Fluorometric Substrate Assay for Cathepsin L1 Activity—Cathepsin
L1 activity was determined by the fluorometric substrate assay de-
scribed by Dowd et al. (38). Yeast culture supernatants or purified
recombinant protease were assayed in a total volume of 1 ml of sub-
strate/buffer mix (2.5 mM EDTA, 2 mM DTT, 0.1 M sodium phosphate
buffer, pH 6.0, and 10 M Z-Phe-Arg-NHMec). The reaction was incu-
bated at 37 °C and stopped after 30 min by the addition of 200 l of 10%
acetic acid. Fluorescence was recorded at an excitation wavelength of
370 nm and an emission wavelength of 440 nm. The activity of the
samples were calculated from a standard curve of NHMec ranging from
0 to 10 M, and presented as nanomoles of NHMec min1 ml1.
In Vitro Processing of Procathepsin L1 and Gly26 Procathepsin L1—
Purified recombinant procathepsin L1 (5 g) was incubated in acti-
vation buffer (0.1 M sodium citrate buffer, pH 5.0, 1 mM DTT, and 1.25
mM EDTA) at 37 °C. Samples were taken at various time points up to
2 h and the proteolytic cleavage of the propeptide visualized by 12%
SDS-PAGE. Aliquots were also assayed for enzyme activity with the
specific substrate Z-Phe-Arg-NHMec as described above.
Exogenous processing of Gly26 procathepsin L1 was carried out by
mixing 5 g of the purified mutant enzyme with 0.5 g of wild-type
procathepsin L that had been activated as described above. Processing
of the mutant protein over a period of 3 h at 37 °C was analyzed by 12%
SDS-PAGE. To confirm that [Gly26]procathepsin L1 was expressed as a
correctly folded protein a similar experiment was performed in parallel
with mutant enzyme preparations that had been unfolded by heating at
95 °C for 3 min.
Identification of Cleavage Products by N-terminal Sequencing—Fol-
lowing 12% SDS-PAGE, proteins were transferred to polyvinylidene
difluoride membrane using a semidry transfer cell at 15V for 20 min.
The membrane was washed with dH2O and stained with 0.025% Coo-
massie Brilliant Blue R-250 in 40% methanol (40). Protein bands of
interest were subjected to N-terminal sequencing at Genosphere Bio-
technologies (Paris, France).
Sequence Analysis—The F. hepatica cathepsin L1 protein sequence
was aligned with several related cathepsin sequences using ClustalX
1.81. Protein sequences used included Carica papaya, Fasciola hepatica
cathepsin L1, F. hepatica cathepsin L2, F. gigantica cathepsin L1,
Schistosoma mansoni cathepsin L2, Caenorhabditis elegans CPL-1,
mouse cathepsin L, rat cathepsin L, and human cathepsin L.2 Se-
quences were numbered according to the papain numbering used by
Vernet et al. (32) where the propeptide residues are recorded as a
negative beginning from the cleavage site between propeptide and
mature enzyme.
SDS-PAGE and Immunoblotting—Protein samples were separated
by 12% SDS-PAGE and gels stained with a 0.1% w/v solution of Coo-
massie Brilliant Blue R-250 in 40% methanol/10% acetic acid (42).
Immunoblots were prepared by transferring proteins to nitrocellulose
membranes, presoaked in a transfer buffer (50 mM Tris, 384 mM glycine,
20% methanol), and then blocking these for 1 h at room temperature
with 5% milk in PBS/0.1% Tween 20. The nitrocellulose membranes
were probed with polyclonal rabbit antimature cathepsin L1 serum,
rabbit anti-recombinant propeptide and preimmunized control rabbit
serum diluted 1/1,000 in 1% milk/PBS/0.1% Tween-20 for 45 min at
room temperature. They were then washed three times for 5 min each
with 1% milk/PBS/0.1% Tween-20, followed by incubation for 45 min at
room temperature with a 1/10,000 dilution of secondary antibody (goat
anti-rabbit IgG-peroxidase conjugate) prepared in 1% milk/PBS/0.1%
Tween-20. Blots were washed as before and bound antibody visualized
with 3,3-diaminobenzidine (DAB, Sigma).
RESULTS AND DISCUSSION
Secretion of Cathepsin L Proteases by F. hepatica Parasites—
When adult F. hepatica are maintained in vitro they secrete
two major proteases that were previously characterized as 27.5
cathepsin L1 and 29 kDa cathepsin L2 in our laboratory (4, 38).
N-terminal sequencing revealed a sequence AVPDK for both
enzymes that correlated with the N terminus of fully processed
mature cathepsin L enzymes. In addition, immunoblotting ex-
periments demonstrated that while they are both reactive with
sera prepared against purified mature cathepsin L1, neither
reacts with sera prepared specifically against a recombinant
propeptide of cathepsin L1 (Fig. 1, see also Fig. 3B). Isolation of
cDNAs encoding the two enzymes showed that they exhibit a
high level of identity (77%) at the amino acid level that explains
their cross-reactivity with antiserum prepared against either
enzyme (13, 38).
The two proteases are members of a phylogenetic lineage
2 Protein sequences and accession numbers from GenBankTM are as
follows: Carica papaya papain (P00784), F. hepatica cathepsin L1
(U62288), F. hepatica cathepsin L2 (U62289), F. gigantica cathepsin L1
(AF112566), S. mansoni cathepsin L2 (Z32529), C. elegans CPL-1
(NP_507199), mouse cathepsin L (P06797), rat cathepsin L (KHRTL),
and human cathepsin L (M20496).
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that includes the mammalian cathepsin Ls and have substrate
specificities that are typical of this group, i.e. a preference for
positively charged residues, such as arginine, in the P1 position
and hydrophobic residues, such as phenylalanine and leucine,
in the P2 position (14). In contrast to mammalian cathepsin Ls,
however, the enzymes exhibit activity over a wide pH range
(4.0–8.5) and are remarkably stable at neutral pH; they retain
most of their activity following a 24-h incubation at pH 7.0 and
37 °C whereas human cathepsin L is completely inactivated in
less than 20 min under the same conditions (43). These en-
hanced stability properties were suggested to be important in
host protein digestion in the parasite gut and in facilitating the
migration of the parasite through the host intestine and liver
(33).
Immunolocalization and in situ hybridization studies previ-
ously carried out by our laboratories had shown that the ca-
thepsin L proteases are synthesized within the gastrodermis
that lines the parasite gut (4, 33). The gastrodermis is com-
posed of epithelial cells that are columnar in shape and contain
numerous dense vesicles situated at the apical end (see Fig.
2A). Although secretory in function, these vesicles have been
described as lysosomal-like and for almost thirty years have
been suspected to contain proteases (44–47). Confocal laser
immunocytochemistry using antiserum prepared against the
native mature cathepsin L localized this protease to the gas-
trodermal epithelial cells (Fig. 2B) throughout the gut of adult
F. hepatica. The pattern of immunoreactive labeling appeared
punctate and was more dense toward the apical end of the
gastrodermal cells indicating that the cathepsin L protease was
associated with the secretory vesicles (Fig. 2C). Electron mi-
croscopy revealed that the enzyme is indeed stored in secretory
vesicles within these cells (Fig. 2, D–F). The secretory vesicles
were strongly immunoreactive with an antiserum prepared
against the recombinant-expressed propeptide (Fig. 2E) and to
the mature portion of cathepsin L1 (Fig. 2F) indicating that the
enzymes are present in these vesicles as the inactive proforms,
procathepsin L. (The specificity of the sera for the propeptide
and mature regions of the procathepsin L1 is demonstrated in
Fig. 3B.)
The above observations provide important insights into the
regulation of protease activity within the gastrodermis of these
parasites. First, in agreement with the observation by Halton
and co-workers (44, 46, 47) it appears that the function of the
vesicles is to package proteolytic enzymes for delivery into the
gut lumen. Second, the accumulation of procathepsin L1, the
inactive precursor, in the secretory vesicles rather than active
mature protease makes good sense given the high abundance of
these vesicles in the epithelial cells and hence the possibility of
protease leakage into the cytoplasm (see Fig. 2A). Third, the
data suggest that activation of the procathepsin L1 takes place
following secretion of the proteases into the gut lumen. Elec-
tron microscopy has shown that the contents of the secretory
vesicles are extruded into the gut lumen where they mix with
the ingested blood and tissue meal between the long extruding
lamellae (Refs. 47 and 48; see Fig. 2A). Enzyme activation is
likely to take place here as the pH is estimated to be 5.5 or
slightly lower (47, 48). Once activated, the protease would be in
direct contact with the bloodmeal and could immediately begin
its function in protein catabolism. Since these helminth para-
FIG. 1. SDS-PAGE and immunoblot analysis of F. hepatica ex-
cretory-secretory (ES) products. ES products obtained from me-
dium in which F. hepatica were cultured was analyzed by SDS-PAGE
and immunoblotting. Lane M, molecular size markers; lane 1, Coomas-
sie Blue-stained 12% SDS-PAGE gel of ES products; lane 2, ES products
probed with antiserum prepared in rabbits against native mature ca-
thepsin L1; lane 3, ES products probed with antiserum prepared in
rabbits against recombinant propeptide of procathepsin L1; lane 4, ES
products probed with normal rabbit serum. Arrows indicate position of
major secreted and fully processed cathepsin L1 and cathepsin L2.
FIG. 2. Immunolocalization of procathepsin L1 in F. hepatica
gastrodermal epithelial cells. A, schematic representation of gastro-
dermal epithelial cells in F. hepatica (after Smyth and Halton, Ref. 46).
g, Golgi; gl, gut lamellae; n, nuclei; sb, secretory bodies. B, confocal
scanning laser micrograph showing immunoreactivity for mature ca-
thepsin L1 within the gastrodermis of adult F. hepatica; the nuclei
(arrows) of the gastrodermal cells are clearly visible. gl, gut lamellae;
lu, gut lumen. C, confocal scanning laser micrograph showing immu-
noreactivity for mature cathepsin L1 within the gastrodermal cells of
adult F. hepatica; the nuclei (arrows) of the gastrodermal cells are
clearly visible. Immunoreactivity appears as a punctuate pattern at the
apical end of the cells where the secretory vesicles are located. gm, gut
muscle; lu, gut lumen. D, electron micrograph showing non-reactivity of
secretory bodies (arrows) within the epithelial cells of the gastrodermis
with control preimmunized rabbit serum. gl, gut lamellae. E, electron
micrograph showing the localization F. hepatica procathepsin L1 to
secretory bodies of the gastrodermal epithelial cells with antiserum
prepared against the recombinant propeptide of procathepsin L1. gl,
gut lamellae. F, electron micrograph showing the localization of F. he-
patica cathepsin L1 to secretory bodies of the gastrodermal epithelial
cells with antiserum prepared against purified mature portion of ca-
thepsin L1. Note that the labeling is confined to the contents of the
secretory bodies.
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sites have a blind-ending gut, removal of undigested products
and accumulated hematin is achieved by simply voiding the
contents approximately every 3 h (46, 47). In this way active
mature cathepsin L would be regularly liberated from the
parasite into the surrounding intestinal or liver tissues where
it could perform its function in tissue degradation and thus aid
the movement of the parasite through these tissues (47, 49).
The secretion of F. hepatica procathepsin contrasts with the
intracellular trafficking of mammalian procathepsin L through
the Golgi apparatus to acidic lysosomes where the enzyme is
processed to the mature form by removal and degradation of
the propeptide (14, 15). However, a low level of procathepsin L
is also secreted from normal cells and is thought to play an
extracellular processing function (50), while high levels of se-
cretion has been correlated with the metastatic activity of
transformed cells (51, 52). A comparison may also be made with
human cathepsin K, which is secreted by osteoclasts and func-
tions in bone resorption (25, 53, 54). Following adherence of
osteoclasts to the bone surface an extracellular compartment
known as an absorption pit is created between cell and bone
into which cathepsin K is secreted. The pH within the pit is
slightly acidic and is considered important not only for the
dissolution of the bone but also for the activation of procathep-
sin K to its active proteolytic form (53, 54). Cathepsin B, L, and
K have also been shown to be secreted into the extracellular
lumen of thyroid follicles where they play a role in the proteo-
lytic processing of covalently cross-linked soluble thyroglobulin
to liberate the thyroid hormone thyroxine (T4) (34–36).
Expression and Processing of Wild-type Procathepsin L1—To
study the mechanism by which the F. hepatica procathepsin L1
is processed to an active mature enzyme the recombinant
proenzyme was expressed in the yeast P. pastoris. The trans-
formed yeast cells were induced by 1% methanol in BMMY
medium buffered at pH 6.0, 7.0, or 8.0 and then the recombi-
nant protein secreted into the medium analyzed by SDS-PAGE.
Two major proteins migrating at 37 and 30 kDa were visualized
(Fig. 3A). These components migrate higher than the mature
cathepsin L1 and cathepsin L2 secreted by the adult F. hepat-
ica parasites in 12% SDS-PAGE (Fig. 3B). Immunoblotting
experiments showed that polyclonal antiserum prepared
against the propeptide portion and against the mature portion
of procathepsin L both reacted with the P. pastoris-expressed
37 and 30 kDa components confirming that these are two forms
of the procathepsin L. By contrast, the fully processed enzymes
secreted by the parasite are reactive with antiserum prepared
against the mature portion of the procathepsin L1 but are not
reactive with antiserum prepared against the propeptide por-
tion (Fig. 3B).
The 37 and 30 kDa components were purified from the pH
8.0 yeast medium by Ni-NTA agarose affinity chromatography
and subjected to N-terminal sequence analysis. This showed
that the 37 kDa protein represented the procathepsin L (plus 5
amino acids of the yeast -factor secretory signal at the N
terminus) while the 30-kDa component represented an inter-
mediate processed form beginning at residue Leu41 (papain
numbering) within the propeptide (see Fig. 5).
The amount of the recombinant proteins in the yeast me-
dium increased over the 3 days following induction with meth-
anol; this increase was observed at pH 6.0, 7.0, and 8.0 (Fig. 3).
However, the relative ratio of the 37 and 30 kDa proteins was
dependent on the buffering pH of the medium, with the pro-
portion of 37 kDa increasing with increasing pH. A pH profile
of activity for the recombinant F. hepatica cathepsin L showed
that it was similar to that of the native mature enzyme (38, 43),
i.e. the recombinant enzyme was active over the pH range 4.0
to 8.5 but was most active at pH 6.0.3 Therefore, by increasing
the pH of the yeast medium above the pH optimum for activity
of the F. hepatica cathepsin L the level of processing of the
37-kDa form to the 30-kDa intermediate form was reduced.
To address this issue further, yeast cells were cultured at pH
8.0 in the presence and absence of the cathepsin L-specific
inhibitor Z-Phe-Ala-CHN2 (Fig. 4, A and B). Although the in-
hibitor was added twice daily at a concentration of 25 M,
which is 250-fold greater than its Ki for cathepsin L (38, 40),
samples of medium taken daily showed that cathepsin L activ-
ity was not completely inhibited (it is possible that the inhibitor
is not stable in the medium) (see Fig. 4B). Nevertheless, the
proportion of 37-kDa component in culture supernatants con-
taining inhibitor was greater than that in cultures without
inhibitor, although the 30-kDa protein was still evident. These
data support the idea that procathepsin L1 secreted from P. pas-
toris autoprocesses to an intermediate active form and that this
autoprocessing is prevented by the cathepsin L protease inhib-
itor Z-Phe-Ala-CHN2. Estimations of yeast cell viability
showed that at the concentrations used the inhibitor did not
affect the growth of the yeast cells.3
To examine whether further intermolecular processing could
take place at a pH lower than 6.0, the 37 kDa procathepsin L1
and 30-kDa intermediate forms were first purified from pH 8.0
yeast culture supernatant by affinity chromatography on Ni-
NTA agarose and dialyzed against PBS (pH 7.3). The pH of
3 P. R. Collins and J. P. Dalton, unpublished data.
FIG. 3. SDS-PAGE and immunoblot analysis of F. hepatica pro-
cathepsin L1 expression from P. pastoris. A, cultures of P. pastoris
transformed with a cDNA encoding procathepsin L1 were induced with
1% methanol. Fermentations were carried out at 30 °C in media buff-
ered to pH 6.0, 7.0, and 8.0. Aliquots (10 l) removed at 48 and 72 h
after induction were analyzed by 12% SDS-PAGE. The 37 and 30 kDa
components are indicated. B, comparison of P. pastoris-expressed pro-
cathepsin L with native F. hepatica-secreted mature cathepsin L1.
Aliquots of adult F. hepatica ES products (lanes 1, 3, and 5) were
compared with samples taken from P. pastoris medium after induction
for 72 h at pH 8.0 (lanes 2, 4, and 6). Lane M, molecular size markers;
panel a, Coomassie Blue-stained 12% SDS-PAGE gel; panel b, samples
probed with antiserum prepared in rabbits against mature portion of
cathepsin L1; panel c, samples probed with antiserum prepared in
rabbits against recombinant propeptide portion of procathepsin L1.
Note, the antipropeptide serum reacts with the 37 and 30 kDa P.
pastoris-expressed components (indicated with arrows) but not with
parasite-produced mature cathepsin L1 or cathepsin L2 (indicated by
an asterisk). Control preimmunized rabbit serum was not reactive with
any proteins (not shown).
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samples taken from this preparation were then reduced to 5.0
by the addition of 0.1 M sodium citrate containing 1 mM DTT
and 1.25 mM EDTA, and then incubated at 37 °C (Fig. 5).
Analysis of samples removed at various time points over a
period of 2 h revealed that the 37 kDa procathepsin L is
processed to the 30-kDa intermediate form and then through
various intermediates that eventually give rise to a single
peptide migrating at 25.4 kDa. Corresponding with this proc-
essing was the gradual 5-fold increase in the activity of cathep-
sin L by the end of the 2-h incubation period (data not shown).
N-terminal sequence analysis of the 25.4 kDa product revealed
two sequences, NRAVP and RAVPD, which are just 2 and 1
amino acids from the mature protein processing site, respec-
tively (see Fig. 5). This intermolecular processing was com-
pletely inhibited by adding 10 M Z-Phe-Ala-CHN2 to the start-
ing mix and therefore can be attributed to the action of
cathepsin L (data not shown).
The cleavage site between Gly42-Leu41 that generated the
30 kDa intermediate form observed by SDS-PAGE analysis
(29.6 kDa from amino acid sequence) was of particular interest
as it occurred within the Gly42-Xaa-Asn-Xaa-Phe-Xaa-Asp36
motif that was previously identified as pivotal in the intermo-
lecular processing of papain expressed in the yeast S. cerevi-
siae. By random mutagenesis studies, and by sequence com-
parisons of various papain-like proteases, Vernet et al. (32)
showed that the Gly42 and Asp36 residues within this motif
were the most constrained and proposed that two cleavage
sites, Gly42-Leu41 and Ala37-Asp36 were important for
proenzyme processing. The latter was considered more signif-
icant because cleavage at this site was predicted to perturb the
negative charge of the Asp36 residue (32). The Asp36 residue
is absolutely conserved in non-cathepsin B-like cysteine pro-
teases of helminth parasites, plants and mammals (including
cathepsin L, cathepsin S, and cathepsin K) and crystallo-
graphic studies on human cathepsin L showed that it partici-
pates in an important salt bridge between propeptide and ma-
ture enzyme (14).
On inspection of the F. hepatica procathepsin L propeptide
sequence we found that the Gly42-Xaa-Asn-Xaa-Phe-Xaa-
Asp36 motif is completely conserved in this parasitic helminth
and in others including F. gigantica and S. mansoni, and in the
free-living helminth C. elegans (Fig. 6). Moreover, the Leu41
residue is also conserved in all of these sequences thus preserv-
ing the Gly42-Leu41 bond and implicating its importance in
propeptide function in these helminths. However, these two
residues are not conserved in the human, mouse, and rat ca-
thepsin L sequences where Gly42 is replaced by Glu or Ala and
Leu41 is replaced by Met (Fig. 6). While it is tempting to
speculate that the changes at these positions explains why an
intermediate 30-kDa form was not observed in studies on the
intermolecular processing of human procathepsin L (15), Mc-
Queney et al. (25) found that the intermolecular processing of
an inactive mutant form of procathepsin K by activated cathep-
sin K did involve a cleavage between Ala42 and Met41. As
pointed out by Coulombe et al. (14), while there may be a direct
involvement of the Asp36 in the Gly42-Xaa-Asn-Xaa-Phe-
Xaa-Asp36 motif in the pH-dependant processing of proforms
of cysteine proteases, cleavage at other peptide bonds within
this motif could influence the local charge state that then may
trigger processing.
Expression and Exogenous Processing of Gly26 Procathepsin
L1—To further study the intermolecular processing of F. he-
patica procathepsin L1 we expressed an inactive form of the
protein by replacing the active site Cys26 with Gly26. Expres-
sion of this recombinant mutant in medium buffered at pH 6.0
FIG. 4. Production of procathepsin L1 by transformed P. pas-
toris in the presence and absence of Z-Phe-Ala-diazomethyl-
ketone. A, transformed P. pastoris were cultured at 30 °C and pH 8.0
in the presence () or absence () of the cysteine protease inhibitor
Z-Phe-Ala-CHN2 (25 M). Aliquots of culture supernatant, removed
after 48 and 72 h, were analyzed by SDS-PAGE. The 37 and 30 kDa
bands are indicated. B, recombinant yeast cultured in the presence
(dotted line) and absence (solid line) of 25 M Z-Phe-Ala-CHN2. Cathep-
sin L activity in the culture supernatant was measured with the flu-
orogenic substrate Z-Phe-Arg-NHMec. Activity units are presented as
nmol of NHMec released min1 ml1.
FIG. 5. Autocatalytic processing of procathepsin L1 at pH 5.0.
Purified procathepsin L1 (5.0 g) was incubated at 37 °C for 2 h in 0.1
M sodium citrate buffer, pH 5.0, containing 2 mM DTT and 2.5 mM
EDTA. Samples removed at various time points were analyzed by
SDS-PAGE. The predominant proteins of 37, 30, and 24.5 kDa were
subjected to N-terminal sequencing. The schematic indicates the amino
acid sequences surrounding the intermolecular processing sites (ar-
rowed) that generated these components and their location within the
propeptide of procathepsin L1. The box indicates the conserved motif
GXNXFXD.
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and 8.0 showed that it migrates as a single band at 37 kDa in
SDS-PAGE (Fig. 7). N-terminal sequencing confirmed that the
37 kDa protein represented the complete procathepsin L1, and
enzyme assays showed that it lacks activity against the sub-
strate Z-Phe-Arg-NHMec.3 The production of the mutant pro-
cathepsin L1 is almost 4-fold greater than that of the combined
37 and 30 kDa components observed in parallel cultures of
wild-type procathepsin L1 (see Fig. 7). Furthermore, the mu-
tant enzyme did not process to lower molecular size forms when
incubated at pH 5.0.3
Addition of recombinant wild-type cathepsin L1, which was
activated as described above, to the mutant procathepsin L, at
pH 5.0, resulted in the progressive appearance of a minor band
at35 kDa over an incubation period of 3 h and a second major
band at 24.5 kDa that co-migrates with fully active cathepsin L
(the intensity of the 24.5-band increases over the reaction pe-
riod, Fig. 8). N-terminal sequencing attempts were unsuccess-
ful for the 35 kDa protein but a sequence of HGVPY (with less
than 10% GVPYE) was obtained for the 24.5 kDa protein; the
cleavage site is therefore located 10 amino acids prior to the N
terminus of mature cathepsin L1. Experiments in which acti-
vated wild-type cathepsin L1 was added to heat-denatured
mutant procathepsin L showed that the latter was sensitive to
complete degradation by active cathepsin L1 and confirms that
the expressed mutant is correctly folded (intensity of the 24.5
does not increase, compare Fig. 8, A and B).
An overview of the cleavage sites observed by autoactivation
by the wild-type enzyme and by intermolecular processing of
mutant enzyme by exogenously added wild-type cathepsin L1
is shown in Fig. 9. The cleavage sites determined for the native
mature cathepsin secreted by F. hepatica parasites in vitro are
also indicated. It is clear that autoactivation and intermolecu-
lar activation occur by cleavages at different sites and thus
processing of procathepsin L1 to an active enzyme can be
achieved by more than one pathway. Of particular note is the
absence of a cleavage site within the Gly42-Xaa-Asn-Xaa-Phe-
Xaa-Asp36 motif that would generate the 30-kDa intermedi-
ate component by exogenous activation. The dominance of this
cleavage site in yeast-expressed wild-type cathepsin L and the
strict conservation of the four relevant residues suggests an
important role for this motif in the processing of F. hepatica
procathepsin L1. The importance of this motif in the processing
of papain was demonstrated by Vernet et al. (32) using various
mutants in Gly42-Xaa-Asn-Xaa-Phe-Xaa-Asp36 sequence;
certain residue replacements gave rise to some non-functional
incorrectly folded enzymes, while others cause the accumula-
tion of inactive or partly active precursors.
Further intermolecular processing and activation of the 30-
kDa intermediate component and direct activation of proca-
thepsin L1 by exogenous enzyme took place in the C-terminal
portion of the propeptide. Elucidation of the three-dimensional
structure of human procathepsin L (14) and cathepsin B (29,
30) revealed that this part of the propeptide is less structured
and is readily accessible to proteases. Testament to this fact is
the collective data showing that papain (32) cathepsin L (14),
cathepsin B (29, 30), cathepsin S (31), and cathepsin K (25) can
all be activated to mature enzymes either by cis- or trans-
cleavage at various bonds within this segment. Cathepsin B of
the helminth parasite S. mansoni can also be activated by
FIG. 6. Comparison of the GXNXFXD motif between papain
and cathepsin L proteases of helminths and mammals. The
GXNXFXD motif sequence of papain is identical to that of F. hepatica
cathepsin L1 and cathepsin L2 and to the cathepsin Ls of related the
trematodes F. gigantica and S. mansoni (identical residues highlighted
in black). The arrow indicates the position of the intermolecular cleav-
age site, between the Gly42-Leu41 bond (papain numbering), that
generates the intermediate 30 kDa component of the F. hepatica pro-
cathepsin L when it is expressed in P. pastoris. The Gly42 is substi-
tuted for Glu in the rat and mouse cathepsin L sequences, and for Ala
in the human cathepsin L sequence (highlighted in gray, papain
numbering).
FIG. 7. Secretion of the mutant procathepsin L1 from P. pas-
toris. P. pastoris cells transformed with wild-type procathepsin L1 (wt)
or the procathepsin L1 that had the active site Cys26 replaced by Gly
(mut) were cultured at 30 °C in media buffered to pH 6.0 and 8.0. After
48 h of induction with 1% (v/v) methanol samples of culture superna-
tant were analyzed by SDS-PAGE. The 30-kDa intermediate form of
procathepsin L was observed only in the wild-type cultures.
FIG. 8. Intermolecular processing of procathepsin L1 Cys26-
Gly26 mutant by exogenously added active cathepsin L1. A, pu-
rified procathepsin Cys26-Gly26 mutant (5.0 g) was incubated for up to
3 h in 0.1 M sodium citrate buffer, pH 5.0, containing 1 mM DTT and
1.25 mM EDTA at 37 °C in the presence of 0.5 g of wild-type cathepsin
L1 that was activated according to procedures shown in Fig. 5. The
position of the mature wild-type cathepsin L at 24.5 kDa (2.5 g,
loading) is indicated in the lane labeled wt with the arrow. B, parallel
experiments were carried as above but in this case purified procathep-
sin Cys26-Gly26 mutant (5.0 g) was unfolded by heating at 95 °C for 3
min prior to the addition of activated wild-type cathepsin L1.
FIG. 9. Amino acid sequence of the propeptide of F. hepatica
cathepsin L1 with cleavage sites that lead to activation indi-
cated. The downward solid arrow indicates the cleavage site observed
when native mature cathepsin L1 is secreted in vitro by adult F.
hepatica. The first open arrow indicates the site of cleavage within the
GXNXFXD motif (boxed) that gives rise to the 30 kDa intermediate
component when procathepsin L1 is expressed in P. pastoris, and the
second and third open arrows show the sites of cleavage when this is
further activated in vitro at pH 5.0 (see Fig. 5). The upward solid arrows
show the sites of cleavage of procathepsin Cys26-Gly26 mutant by exog-
enously added mature cathepsin L1.
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trans-cleavage at this segment (55, 56). However, the sites of
cleavage of the wild-type and mutant procathepsin L1 differed
suggesting that prior cleavage within the Gly42-Xaa-Asn-Xaa-
Phe-Xaa-Asp36 motif of the wild-type enzyme may have al-
tered the accessibility of the C terminus to protease action. It is
also evident that both processing pathways leave additional
amino acids at the N terminus of the mature enzyme, whereas
cathepsin L1 recovered from the medium in which parasites
were cultured was fully processed to the characteristic N-ter-
minal residue. This suggests that additional protease action,
possibly by an exopeptidase, may be required to remove these
additional amino acids.
In the present study we show that the secretion and activa-
tion of F. hepatica cathepsin L1 has similarities with that of
their mammalian counterparts. Most importantly, we have
elucidated that cathepsin Ls are secreted into the parasite
lumen from vesicles synthesized within the gastrodermal epi-
thelial cells and that it is possible for these to become active by
autocatalysis within the slightly acidic environment of the gut.
The cathepsin L proteases are synthesized in copious amounts
by F. hepatica parasites (0.5–1.0 g per adult parasite per
hour) and early autoradiographic studies by Hanna (57) esti-
mated that the turnover rate from the synthesis of the contents
of the secretory vesicles to their liberation into the gut lumen
was rapid (1 h). The means by which these enzymes are
trafficked to the secretory vesicles and the possible involve-
ment of the Gly42-Xaa-Asn-Xaa-Phe-Xaa-Asp36 motif (32) or
a pH-dependent interaction with a membrane-bound receptor
(58) requires investigation. A role for carbohydrate moieties
may be excluded since the F. hepatica procathepsin L studied
here contains no potential N-glycosylation sites, and studies
have indicated that the native enzyme is not glycosylated (38,
42), although homologs from other helminths, such a S. man-
soni, are glycosylated (59).
Mammalian cathepsins play a number of important biologi-
cal functions such as protein turnover, antigen processing and
tissue remodeling (50). However, they have also been impli-
cated in various pathological conditions including tumor inva-
sion and metastasis (50, 60, 61), osteoporosis (53, 54, 62), and
chronic inflammatory disease (63, 64). In parasites, cysteine
proteases perform a number of pivotal functions such as feed-
ing, tissue penetration and immunomodulation that allow
them to infect and establish disease in the host (2, 56). A
number of studies have demonstrated that these enzymes rep-
resent targets at which new chemotherapeutic and immuno-
prophylactic strategies can be directed (2, 12, 56, 65). While the
goal of improving our knowledge on the activation mechanisms
of mammalian cathepsin protease is to provide new ways of
treating the diseases they cause, similar studies on the para-
site homologs would allow comparative analyses for the pur-
pose of designing parasite-specific treatments. The feasibility
of this approach was demonstrated in our laboratory by show-
ing that propeptides of F. hepatica procathepsin Ls are potent
inhibitors of their cognate enzymes but exhibit little or no
activity against their mammalian homologs.
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